Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced lung adenocarcinoma patients with specific EGFR mutations benefit from EGFR tyrosine kinase inhibitors (TKIs).
• Comparing the efficacy of different generations of EGFR TKIs is crucial for optimizing treatment strategies.

Purpose of the Study:

• To compare the effectiveness of first-generation (1st G), second-generation (2nd G), and third-generation (3rd G) EGFR TKIs in patients with advanced lung adenocarcinoma and sensitizing EGFR mutations.

Main Methods:

• Retrospective analysis of 421 patients with stage IV lung adenocarcinoma receiving first-line EGFR-TKI therapy.
• Comparison of progression-free survival (PFS) and overall survival (OS) across different EGFR TKI generations (1st G: gefitinib/erlotinib, 2nd G: afatinib, 3rd G: osimertinib).

Main Results:

• Third-generation (3rd G) EGFR TKIs demonstrated significantly better PFS and OS compared to 1st G and 2nd G TKIs (PFS p=0.0002, OS p=0.0215).
• Patients with exon 19 deletion showed particular benefit from 3rd G EGFR TKIs.
• A higher T790M mutation rate was observed in patients receiving 1st G EGFR TKIs, those with exon 19 deletion, and those with PFS ≥ 270 days.
• No significant survival difference was found between frontline 3rd G EGFR TKI and sequential 3rd G EGFR TKI therapy (OS p=0.1941).
• Patients not receiving sequential 3rd G EGFR TKI therapy had significantly worse OS compared to those receiving it first-line (OS p=0.0042).

Conclusions:

• Third-generation (3rd G) EGFR TKIs may offer superior survival benefits as first-line therapy for advanced lung adenocarcinoma patients with sensitizing EGFR mutations.
• The benefit of 3rd G EGFR TKIs is particularly pronounced in patients with the exon 19 deletion mutation.